Stocktoria
Kymera Therapeutics, Inc. KYMR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-08-21
Kymera Therapeutics, Inc. statistics & valuation
Market cap$8.9B
P / B5.6×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% |
| Net margin | -794.0% | -475.6% | -187.0% | -330.6% | -137.6% |
| FCF margin | -597.6% | -440.5% | -174.7% | -333.0% | -179.2% |
| Return on assets | -17.9% | -22.9% | -25.5% | -25.7% | -16.5% |
| Return on equity | -19.7% | -26.8% | -37.2% | -31.6% | -21.8% |
| Current ratio | 10.47 | 7.53 | 4.73 | 5.88 | 4.88 |
| Revenue growth | -16.7% | -40.1% | 67.8% | -35.7% | 114.0% |
Source: SEC EDGAR filings · CIK 0001815442 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.